GenSight Biologics Inc.
Envisioning gene therapies for the eye
This article was originally published in Start Up
Gene therapy start-up GenSight Biologics Inc. will use its recent €32 million Series A financing to develop its preclinical gene therapies for rare and blinding ophthalmic diseases. The company will develop two therapies: one for Leber’s hereditary optic neuropathy, a degradation of the optic nerve that results from a mitochondrial DNA mutation, and an optogenetic therapy addressing retinitis pigmentosa, among the most common inherited causes of blindness in people below the age of 50.
You may also be interested in...
The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.
Lots of early money, or just a little? In the six years of data we examined, it didn’t matter what a biotech received; there was no correlation to the size of the company’s acquisition price or public market capitalization.
With one of the largest VC-funded financings in Europe this year, the German biotech receives sufficient funds to allow it to prepare marketing submissions for its lead renal cancer vaccine.